Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
59 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Narcolepsy - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Narcolepsy - Pipeline Review, H2 2014', provides an overview of the Narcolepsy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Narcolepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Narcolepsy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Narcolepsy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Narcolepsy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Narcolepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Narcolepsy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Narcolepsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Narcolepsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Narcolepsy Overview 7 Therapeutics Development 8 Pipeline Products for Narcolepsy - Overview 8 Pipeline Products for Narcolepsy - Comparative Analysis 9 Narcolepsy - Therapeutics under Development by Companies 10 Narcolepsy - Therapeutics under Investigation by Universities/Institutes 12 Narcolepsy - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Narcolepsy - Products under Development by Companies 16 Narcolepsy - Products under Investigation by Universities/Institutes 17 Narcolepsy - Companies Involved in Therapeutics Development 18 Taisho Pharmaceutical Co., Ltd. 18 Evotec AG 19 Jazz Pharmaceuticals plc 20 Flamel Technologies S.A. 21 Grupo Ferrer Internacional, S.A. 22 Concert Pharmaceuticals, Inc. 23 BIOPROJET SCR 24 SK Biopharmaceuticals Co., Ltd. 25 Spherium biomed S.L. 26 Narcolepsy - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 33 Drug Profiles 34 tiprolisant - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 SKL-N05 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 TS-091 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 JZP-386 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 sodium oxybate - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 EVT-501 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 arbaclofen - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 SP-14002 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 C-10291 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Drugs to Target Orexin Receptor for Narcolepsy and Sleep Disorders - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecules to Agonize Orexin Receptor for Narcolepsy and EDS - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Narcolepsy - Recent Pipeline Updates 48 Narcolepsy - Dormant Projects 50 Narcolepsy - Discontinued Products 51 Narcolepsy - Product Development Milestones 52 Featured News & Press Releases 52 Jul 21, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386 52 Jun 02, 2014: Jazz Pharmaceuticals Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy 52 May 27, 2014: Jazz Pharmaceuticals To Present Data On Compound In Sleep Pipeline During APSS Annual SLEEP Meeting 53 Apr 07, 2014: Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate 53 Jun 03, 2013: Aerial BioPharma Announces Presentation Of ADX-NO5 Results At SLEEP 2013 Meeting 54 Dec 17, 2012: FDA Announces Combined Use Of Jazz Pharma's Xyrem With Alcohol Or CNS Depressants May Lead To Respiratory Depression 55 Dec 04, 2012: Jazz Pharma Obtains Additional Xyrem Patent From USPTO 55 Sep 11, 2012: Jazz Pharma Announces Issuance Of New Formulation Patent For Xyrem 56 Aug 29, 2012: Aerial BioPharma Receives FDA Orphan Drug Designation For Narcolepsy Drug In Development 56 Aug 10, 2012: Mylan Launches Generic Provigil Tablets 57 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 59 Disclaimer 59
List of Tables Number of Products under Development for Narcolepsy, H2 2014 8 Number of Products under Development for Narcolepsy - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Number of Products under Investigation by Universities/Institutes, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Products under Investigation by Universities/Institutes, H2 2014 17 Narcolepsy - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2014 18 Narcolepsy - Pipeline by Evotec AG, H2 2014 19 Narcolepsy - Pipeline by Jazz Pharmaceuticals plc, H2 2014 20 Narcolepsy - Pipeline by Flamel Technologies S.A., H2 2014 21 Narcolepsy - Pipeline by Grupo Ferrer Internacional, S.A., H2 2014 22 Narcolepsy - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 23 Narcolepsy - Pipeline by BIOPROJET SCR, H2 2014 24 Narcolepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 25 Narcolepsy - Pipeline by Spherium biomed S.L., H2 2014 26 Assessment by Monotherapy Products, H2 2014 27 Number of Products by Stage and Target, H2 2014 29 Number of Products by Stage and Mechanism of Action, H2 2014 31 Number of Products by Stage and Route of Administration, H2 2014 32 Number of Products by Stage and Molecule Type, H2 2014 33 Narcolepsy Therapeutics - Recent Pipeline Updates, H2 2014 48 Narcolepsy - Dormant Projects, H2 2014 50 Narcolepsy - Discontinued Products, H2 2014 51
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
